GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)
2,878.30
+89.60 (3.21%)
May 14, 2025, 12:31 PM IST
NSE:GLAXO Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 37,492 | 34,537 | 32,517 | 32,780 | 29,256 | Upgrade
|
Other Revenue | 1,459 | - | - | - | - | Upgrade
|
Revenue | 38,951 | 34,537 | 32,517 | 32,780 | 29,256 | Upgrade
|
Revenue Growth (YoY) | 12.78% | 6.21% | -0.80% | 12.05% | -9.27% | Upgrade
|
Cost of Revenue | 13,909 | 13,552 | 13,041 | 13,782 | 12,824 | Upgrade
|
Gross Profit | 25,043 | 20,985 | 19,476 | 18,998 | 16,432 | Upgrade
|
Selling, General & Admin | 5,797 | 7,358 | 7,062 | 7,397 | 6,858 | Upgrade
|
Other Operating Expenses | 6,013 | 4,541 | 4,272 | 3,931 | 3,594 | Upgrade
|
Operating Expenses | 12,478 | 12,595 | 11,992 | 12,010 | 11,236 | Upgrade
|
Operating Income | 12,565 | 8,390 | 7,484 | 6,988 | 5,196 | Upgrade
|
Interest Expense | -13.1 | -17.99 | -18.12 | -19.96 | -35.31 | Upgrade
|
Interest & Investment Income | - | 729.28 | 698.55 | 711.53 | 1,106 | Upgrade
|
Currency Exchange Gain (Loss) | - | - | -99.07 | -51.36 | - | Upgrade
|
Other Non Operating Income (Expenses) | - | - | - | 37 | 0.08 | Upgrade
|
EBT Excluding Unusual Items | 12,552 | 9,101 | 8,066 | 7,666 | 6,266 | Upgrade
|
Merger & Restructuring Charges | - | -1,633 | -113.7 | -200.84 | -2.4 | Upgrade
|
Gain (Loss) on Sale of Investments | - | 487.76 | 307.79 | 5.92 | - | Upgrade
|
Gain (Loss) on Sale of Assets | - | 8.89 | 0.28 | 3.24 | -0.59 | Upgrade
|
Asset Writedown | - | - | - | 2.61 | -2,090 | Upgrade
|
Other Unusual Items | 46.9 | 196.87 | 104.02 | 314 | 366.44 | Upgrade
|
Pretax Income | 12,599 | 8,162 | 8,364 | 7,790 | 4,540 | Upgrade
|
Income Tax Expense | 3,323 | 2,262 | 2,288 | 3,983 | 1,667 | Upgrade
|
Earnings From Continuing Operations | 9,276 | 5,900 | 6,076 | 3,808 | 2,873 | Upgrade
|
Earnings From Discontinued Operations | - | - | 30.45 | 13,140 | 708.78 | Upgrade
|
Net Income | 9,276 | 5,900 | 6,107 | 16,947 | 3,581 | Upgrade
|
Net Income to Common | 9,276 | 5,900 | 6,107 | 16,947 | 3,581 | Upgrade
|
Net Income Growth | 57.23% | -3.39% | -63.97% | 373.19% | 284.26% | Upgrade
|
Shares Outstanding (Basic) | 169 | 169 | 169 | 169 | 169 | Upgrade
|
Shares Outstanding (Diluted) | 169 | 169 | 169 | 169 | 169 | Upgrade
|
Shares Change (YoY) | -0.01% | - | - | - | - | Upgrade
|
EPS (Basic) | 54.76 | 34.83 | 36.05 | 100.04 | 21.14 | Upgrade
|
EPS (Diluted) | 54.76 | 34.83 | 36.05 | 100.04 | 21.14 | Upgrade
|
EPS Growth | 57.24% | -3.39% | -63.97% | 373.19% | 284.26% | Upgrade
|
Free Cash Flow | 12,669 | 5,508 | 4,402 | 7,761 | 5,337 | Upgrade
|
Free Cash Flow Per Share | 74.79 | 32.51 | 25.98 | 45.81 | 31.50 | Upgrade
|
Dividend Per Share | - | 32.000 | 32.000 | 30.000 | 30.000 | Upgrade
|
Dividend Growth | - | - | 6.67% | - | 50.00% | Upgrade
|
Gross Margin | 64.29% | 60.76% | 59.89% | 57.96% | 56.17% | Upgrade
|
Operating Margin | 32.26% | 24.29% | 23.02% | 21.32% | 17.76% | Upgrade
|
Profit Margin | 23.81% | 17.08% | 18.78% | 51.70% | 12.24% | Upgrade
|
Free Cash Flow Margin | 32.52% | 15.95% | 13.54% | 23.68% | 18.24% | Upgrade
|
EBITDA | 13,233 | 8,805 | 7,884 | 7,428 | 5,733 | Upgrade
|
EBITDA Margin | 33.97% | 25.50% | 24.25% | 22.66% | 19.60% | Upgrade
|
D&A For EBITDA | 667.9 | 415.36 | 399.67 | 439.6 | 537.22 | Upgrade
|
EBIT | 12,565 | 8,390 | 7,484 | 6,988 | 5,196 | Upgrade
|
EBIT Margin | 32.26% | 24.29% | 23.02% | 21.32% | 17.76% | Upgrade
|
Effective Tax Rate | 26.38% | 27.72% | 27.35% | 51.12% | 36.72% | Upgrade
|
Revenue as Reported | 38,951 | 35,763 | 33,524 | 33,538 | 30,362 | Upgrade
|
Advertising Expenses | - | 1,094 | 1,091 | 1,277 | 673.72 | Upgrade
|
Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.